European Commission Approves Povofortay for Hidradenitis Suppurativa
The European Commission approved Povofortay (povorcitinib) as a once-daily oral treatment for adults with moderate to severe hidradenitis suppurativa. The approval was based on data from Phase 3 STOP-HS1 and STOP-HS2.
Story updates
09:30:29 PM UTC
SquawkNews
The European Commission approved Incyte’s Povofortay 45 mg and 75 mg for eligible adults with moderate to severe hidradenitis suppurativa. The FDA is reviewing the U.S. application; approval and launch are anticipated in Q1 2027.Material DetailsContext by AI AnalystThis is a commercial-stage regula…
09:33:08 PM UTC
SquawkNews
The European Commission approved Povofortay (povorcitinib) 45 mg and 75 mg for eligible adults with